Modulation of the phospholipase A2 pathway as a therapeutic
View Patent ↗There is provided a method of modifying vasoactivity by regulating a soluble Aβ pro-inflammatory pathway. Also provided is a method of modifying inflammatory reactions in microglia and neurons by regulating a soluble Aβ pro-inflammatory pathway. A method of treating patients with vascular disease by modifying an intracellular soluble Aβ pro-inflammatory pathway is also provided. A pharmaceutical composition consisting essentially of an effective amount of a soluble Aβ pro-inflammatory pathway regulator in a pharmaceutically effective carrier is also provided.
1. A method of modifying beta-amyloid-induced vasoactivity in individuals with Alzheimer's Disease or other vascular-related diseases or disorders, in which said vascular-related diseases or disorders are selected from the group consisting of cerebral amyloid angiopathy, vascular amyloidosis, hypertension and vasospasm associated with severe post-traumatic head injury, comprising antagonizing the secretory phospholipase A2/arachidonic acid/5-lipoxygenase/cyclo-oxygenase-2 pro-inflammatory pathway by administering a pharmaceutically effective amount of oleyloxyethylphosphocholine to the individual in an amount ranging from between 0.1 μg to 10 mg/kg body weight/day.
2. The method according to claim 1 , further defined as down-regulating a soluble Aβ pro-inflammatory pathway.
3. The method of claim 1 , wherein the vascular-related disease or disorder is cerebral amyloid angiopathy.
4. The method of claim 1 , wherein the vascular-related disease or disorder is vascular amyloidosis.
5. The method of claim 1 , wherein the vascular-related disease or disorder is hypertension.
6. The method of claim 1 , wherein the vascular-related disease or disorder is vasospasm associated with severe post-traumatic head injury.
7. The method of claim 1 , wherein oleyloxyethylphosphocholine is administered orally, subcutaneously, parenterally, intraperitoneally, intranasally or by implant.
8. The method of claim 1 , wherein oleyloxyethylphosphocholine is administered orally.
9. The method of claim 8 , wherein oleyloxyethylphosphocholine is administered in a pharmacological formulation in the form of a tablet, suspension, solution, emulsion, capsule, powder, or syrup.
10. A method of treating cerebral amyloid angiopathy, vascular amyloidosis, hypertension or vasospasm associated with severe post-traumatic head injury in an individual, the method comprising administering a pharmaceutically effective amount of oleyloxyethylphosphocholine to the individual.